Treating Nightmares May Be a Powerful Suicide Prevention Strategy
New research clarifies how nightmare-focused therapies like IRT and prazosin could reduce suicide risk in vulnerable patients.
Summary
Nightmares are increasingly recognized as more than a symptom — they may be an independent risk factor for suicidal ideation and behavior. This paper from French psychiatric researchers at Université Paris Cité and AP-HP examines the role of two nightmare-focused interventions — Imagery Rehearsal Therapy (IRT), a cognitive-behavioral technique, and prazosin, an alpha-1 adrenergic antagonist — in the context of suicide prevention. Based on the title, the authors aim to 'clarify the role' of these interventions, suggesting a nuanced appraisal of the evidence rather than a blanket endorsement. Note: this summary is based on title and metadata only, as the article's abstract and full text were not accessible at the time of review.
Detailed Summary
Nightmares have historically been treated as secondary symptoms of psychiatric conditions such as PTSD or depression. A growing body of evidence, however, suggests chronic nightmares may independently contribute to suicidal ideation and behavior — raising the question of whether targeted nightmare treatment could serve as a suicide prevention strategy.
This paper, authored by Maruani and Geoffroy of Université Paris Cité and AP-HP's Bichat - Claude Bernard psychiatric division, addresses the roles of two nightmare-focused interventions: Imagery Rehearsal Therapy (IRT), a cognitive-behavioral technique in which patients rescript distressing dream content during waking hours, and prazosin, an alpha-1 adrenergic receptor antagonist that has been used off-label for trauma-related nightmares. The title's framing — 'Clarifying the Role of' — suggests the authors aim to refine or qualify current understanding of these interventions in suicide prevention, rather than offer an unqualified endorsement.
Important caveat: this summary is based solely on the article's title, author information, and journal metadata. The abstract and full text were not available at the time of review, so the specific arguments, evidence cited, conclusions, and any recommendations the authors make cannot be reported here. Readers should consult the published article directly (Sleep, June 2026; DOI: 10.1093/sleep/zsag151) for the substantive content.
Context from the broader literature — not necessarily reflective of this paper's position — is that IRT has accumulated supportive evidence for reducing nightmare frequency, while prazosin's efficacy for PTSD-related nightmares has been contested following a large VA cooperative trial (Raskind et al., NEJM 2018) that did not show benefit over placebo, despite earlier positive studies. A paper titled 'Clarifying the Role' may engage with precisely this kind of contested evidence base.
Key Findings
- The paper addresses two nightmare-focused interventions — Imagery Rehearsal Therapy (IRT) and prazosin — in the context of suicide prevention.
- The title's framing ('Clarifying the Role of') suggests a nuanced reappraisal rather than a blanket endorsement.
- Published in Sleep (June 2026) by Maruani and Geoffroy of Université Paris Cité and AP-HP psychiatric services.
- Specific findings, recommendations, and evidence synthesis cannot be reported: only title and metadata were available for review.
- Readers should consult the full article (DOI: 10.1093/sleep/zsag151) for substantive content.
Methodology
Based on the title and journal, this appears to be a commentary, editorial, or perspective piece in Sleep rather than original empirical research, but this classification cannot be confirmed from metadata alone. The full text was not accessible for review.
Study Limitations
This summary is based solely on the article's title, authors, and journal metadata; the abstract and full text were not accessible. As a result, the paper's specific arguments, evidence base, conclusions, and any clinical recommendations are not reported here. Any characterization of mechanisms, efficacy claims, or stance on prazosin's contested evidence base would be speculative.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.